The company made the disclosures as part of Agilent's fiscal second-quarter earnings report, which showed that total revenues grew 16 percent and that a net loss in the prior-year period swung to a profit in the current quarter.
The firms will combine their mass spec and NMR technologies for metabolomic applications.
The revenue from the stimulus orders surpasses a $50 million estimate provided by the firm just a few months ago.
Bruker said that it booked orders from global stimulus programs, and it expects further orders from these programs through the rest of this year and into 2010.
Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.
Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.
NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.
In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.